Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (51-60 of 265) with videos related to

Pageof 27
Sort By:
Menopause (New York, N.Y.)|May 21, 2020
Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trialHarriet Richardson, Vikki Ho, Romain Pasquet, et al.
Breast Cancer (Tokyo, Japan)|October 18, 2021
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerMasato Takahashi, Eriko Tokunaga, Joji Mori, et al.
Breast Cancer Research : BCR|March 20, 2025
Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesteroneJames N Ingle, Vera J Suman, Malvika H Solanki, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 9, 2022
Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen MetabolismEmily J Koubek, Sarah A Buhrow, Stephanie L Safgren, et al.
Academic Radiology|November 8, 2020
MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant ChemotherapySadia Choudhery, Daniel Gomez-Cardona, Christopher P Favazza, et al.
Breast Cancer Research and Treatment|January 1, 2018
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancerTufia C Haddad, Antonino D'Assoro, Vera Suman, et al.
Molecular Cancer Research : MCR|February 25, 2021
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant ModelsCalley J Jones, Malayannan Subramaniam, Michael J Emch, et al.
Human Pathology|September 19, 2009
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancerSejal S Shah, Rhett P Ketterling, Matthew P Goetz, et al.
AJR. American Journal of Roentgenology|July 26, 2011
Palliation of painful metastatic disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoablationPaul G Thacker, Matthew R Callstrom, Timothy B Curry, et al.
Breast Cancer Research and Treatment|May 24, 2019
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapyZahraa Al-Hilli, Grace Choong, Michael G Keeney, et al.
Pageof 27

Showing results (51-60 of 265) with videos related to

Sort By:
Pageof 27
Menopause (New York, N.Y.)|May 21, 2020
Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trialHarriet Richardson, Vikki Ho, Romain Pasquet, et al.
Breast Cancer (Tokyo, Japan)|October 18, 2021
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerMasato Takahashi, Eriko Tokunaga, Joji Mori, et al.
Breast Cancer Research : BCR|March 20, 2025
Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesteroneJames N Ingle, Vera J Suman, Malvika H Solanki, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 9, 2022
Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen MetabolismEmily J Koubek, Sarah A Buhrow, Stephanie L Safgren, et al.
Academic Radiology|November 8, 2020
MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant ChemotherapySadia Choudhery, Daniel Gomez-Cardona, Christopher P Favazza, et al.
Breast Cancer Research and Treatment|January 1, 2018
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancerTufia C Haddad, Antonino D'Assoro, Vera Suman, et al.
Molecular Cancer Research : MCR|February 25, 2021
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant ModelsCalley J Jones, Malayannan Subramaniam, Michael J Emch, et al.
Human Pathology|September 19, 2009
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancerSejal S Shah, Rhett P Ketterling, Matthew P Goetz, et al.
AJR. American Journal of Roentgenology|July 26, 2011
Palliation of painful metastatic disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoablationPaul G Thacker, Matthew R Callstrom, Timothy B Curry, et al.
Breast Cancer Research and Treatment|May 24, 2019
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapyZahraa Al-Hilli, Grace Choong, Michael G Keeney, et al.
Pageof 27